Regarding the HR-negative/HER-2-negative population, our study was underpowered in terms of demonstrating a significant survival benefit in this subtype, and indeed the prognosis was worse for this group than for the other tumor subtypes. The gene discussed is ERBB2; the disease is neoplasm.